Sign Up for a Free Account
  • Updated 07.21.2020
  • Released 05.14.1996
  • Expires For CME 07.21.2023

Systemic lupus erythematosus

Introduction

Overview

Systemic lupus erythematosus is 1 of the best-studied autoimmune diseases that may affect all systems, particularly the central and peripheral nervous systems. Therapies have improved, resulting in better quality of life and lower mortality rates. In this article, the author reviews the diagnostic, pathogenetic, and therapeutic issues of systemic lupus erythematosus, with an emphasis on neurologic and neuropsychiatric lupus. The most recent guidelines for diagnosis and management are presented.

Key points

• The differential diagnosis of NPSLE from CNS infections, metabolic disturbances, primary neuropsychiatric disorders, and drug adverse reactions is important.

• Neuroimaging studies and novel laboratory tests for autoantibodies may aid the diagnosis of neuropsychiatric systemic lupus erythematosus and provide clues for the underlying pathophysiology.

• The prevalence of cognitive dysfunction in systemic lupus erythematosus has not been accurately determined due to lack of uniform criteria used in its definition and diagnostic tests.

• The distinction between major and minor or nonspecific events in neurologic manifestations has a prognostic value because accrual of major neuropsychiatric events and CNS lesions is associated with increased mortality and morbidity.

Historical note and terminology

Even though the term lupus was first used by Rogerius in the 13th century (27), the systemic nature of the disease was established much later by Osler in 1904 (162). A number of laboratory findings have revolutionized the understanding and diagnosis of the disease. The false-positive test for syphilis was first described in lupus by Hauck and Reinhart in 1909. Hargraves and colleagues reported the lupus erythematosus cell in 1948, and Friou developed the fluorescent antinuclear antibody test in 1957. These discoveries established lupus as an autoimmune disease. Since then, defects in immune complex clearance, B-cell tolerance, and T-cell function have been demonstrated (163). The discovery of various autoantibodies and the recognition that the antiphospholipid syndrome (89) can coexist with systemic lupus erythematosus have been important milestones in understanding the disease process. Other landmark observations have included the recognition of drug-induced lupus in 1945 and the establishment of a mouse animal model in 1958.

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com